Ligand-Binding Assay Development: What Do You Want to Measure Versus What You Are Measuring?
Journal Title: The AAPS Journal - Year 2016, Vol 18, Issue 2
Abstract
The analysis of biotherapeutics by ligand-binding assay (LBA) is associated with some unique challenges that are unlike those commonly encountered in chromatographic methods for chemically based small molecule drugs. While small molecule drugs are typically highly protein bound, the use of an extraction procedure disrupts these interactions and thus allows for measurement of total drug concentrations; modeling is subsequently required to estimate the amount of free drug based upon protein-binding data. Protein-binding interactions for small molecule drugs are typically low affinity and high capacity in nature (i.e., albumin binding). In contrast, LBAs are most often used for the quantitation of large molecule proteins or peptides, where the use of an extraction procedure is replaced by sample dilution. Interferences in ligand-binding assays are typically of high affinity and low capacity and include target, receptors, anti-drug antibodies, and binding proteins (1,2), however some are typically low affinity such as anti-drug antibodies. While ligand-binding assays are traditionally the methodology of choice for the quantification of biotherapeutics in biological matrices, there is a trend towards increased use of chromatographic methods. Immunoenrichment and enzymatic digestion followed by the LC-MS/MS monitoring of specific biotherapeutic peptide fragments for use as a surrogate to quantify the whole molecule are becoming emergent techniques in the bioanalyst toolbox (3,4). This diversity in analytical technology often times leads to good-natured debate among bioanalytical scientists who tend to gravitate towards one of the two technological approaches. Yet, during assay development, there are two critical questions that often go unanswered; what do you want to measure and what are you measuring?
Authors and Affiliations
Andrew P. Mayer, Charles S. Hottenstein
Keywords
Related Articles
- EP ID EP680838
- DOI 10.1208/s12248-015-9855-0
- Views 67
- Downloads 0
Current Scientific and Regulatory Approaches for Development of Orally Inhaled and Nasal Drug Products: Overview of the IPAC-RS/University of Florida Orlando Inhalation Conference
This article summarizes discussions at the March 2014 conference organized by the University of Florida (UF) and International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS), entitled “Orla...
Evaluation of α2-Integrin Expression as a Biomarker for Tumor Growth Inhibition for the Investigational Integrin Inhibitor E7820 in Preclinical and Clinical Studies
E7820 is an orally active inhibitor of α2-integrin mRNA expression, currently tested in phases I and II. We aimed to evaluate what levels of inhibition of integrin expression are needed to achieve tumor stasis in...
Anionic liposomal delivery system for DNA transfection
The present study investigates the use of novel anionic lipoplexes composed of physiological components for plasmid DNA delivery into mammalian cells in vitro. Liposomes were prepared from mixtures of endogenously occurr...
DDSolver: An Add-In Program for Modeling and Comparison of Drug Dissolution Profiles
The online version of this article (doi:10.1208/s12248-010-9185-1) contains supplementary material, which is available to authorized users.
A semiautomated approach to gene discovery through expressed sequence tag data mining: Discovery of new human transporter genes
Identification and functional characterization of the genes in the human genome remain a major challenge. A principal source of publicly available information used for this purpose is the National Center for Biotechnolog...